Volume 62, 2022-4-1, Pages i-181
Articles in this issue:
1. Editorial Board
2. Factors influencing five-year adherence to adjuvant endocrine therapy in breast cancer patients: A systematic review
- Pages 22-35.
- Yussof, Izzati, Mohd Tahir, Nor Asyikin, Hatah, Ernieda, and Mohamed Shah, Noraida.
- PDF
3. Psychoeducation for breast cancer: A systematic review and meta-analysis
- Pages 36-51.
- Setyowibowo, Hari, Yudiana, Whisnu, Hunfeld, Joke A.M., Iskandarsyah, Aulia, Passchier, Jan, Arzomand, Homra, Sadarjoen, Sawitri S., de Vries, Ralph, and Sijbrandij, Marit.
- PDF
4. Retrospective literature review of primary neuroendocrine neoplasms of the breast (BNEN) in 209 Chinese patients: Treatment and prognostic factor analysis
- Pages 93-102.
- Chai, Yue, Liu, Ming, Li, Zhijun, Chen, Yujie, Qi, Fei, Li, Qiao, and Xu, Binghe.
- PDF
5. Optimal localization strategies for non-palpable breast cancers –A network meta-analysis of randomized controlled trials
- Pages 103-113.
- Davey, Matthew G., O'Donnell, John P.M., Boland, Michael R., Ryan, Éanna J., Walsh, Stewart R., Kerin, Michael J., and Lowery, Aoife J..
- PDF
6. On top of that all, now Covid-19, too. A scoping review of specificities and correlates of fear of cancer recurrence in breast cancer patients during COVID-19
- Pages 123-134.
- Kállay, Éva, Medrea, Flavia, and Dégi, Csaba László.
- PDF
7. Efficacy of CT-P6 (trastuzumab biosimilar) versus reference trastuzumab in combination with pertuzumab in HER2-positive early-stage breast cancer: Preclinical and real-life clinical data
- Pages 1-9.
- Bernat-Peguera, Adrià, Trigueros, Macedonia, Ferrando-Díez, Angélica, Ibáñez, Cristina, Bystrup, Sara, Martínez-Cardús, Anna, Margelí, Mireia, and Martínez-Balibrea, Eva.
- PDF
8. Safety of pre- or postoperative accelerated radiotherapy in 5 fractions: A randomized pilot trial
- Pages 10-15.
- Vincent, Vakaet, MD, Hans, Van Hulle, PhD, Koen, Van de Vijver, Ingeborg, Hilderson, Eline, Naert, Wilfried, De Neve, Jo, Vandorpe, An, Hendrix, Menekse, Göker, Herman, Depypere, Glenn, Vergauwen, Rudy, Van den Broecke, Pieter, De Visschere, Geert, Braems, Katrien, Vandecasteele, Hannelore, Denys, and Liv, Veldeman.
- PDF
9. Evidence from a BreastScreen cohort does not support a longer inter-screen interval in women who have no conventional risk factors for breast cancer
- Pages 16-21.
- Noguchi, Naomi, Marinovich, Michael Luke, Wylie, Elizabeth Jane, Lund, Helen Gabriel, and Houssami, Nehmat.
- PDF
10. Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer
- Pages 52-60.
- Lee, Soohyeon, Park, Kyunghee, Kim, Gun Min, Jung, Kyung Hae, Kang, Seok Yun, Park, In Hae, Kim, Jee Hyun, Ahn, Hee Kyung, Park, Woong-Yang, Im, Seock-Ah, and Park, Yeon Hee.
- PDF
11. Neuroinflammation as potential precursor of leukoencephalopathy in early-stage breast cancer patients: A cross-sectional PET-MRI study
- Pages 61-68.
- Schroyen, Gwen, Sleurs, Charlotte, Bartsoen, Emilie, Smeets, Dirk, van Weehaeghe, Donatienne, Van Laere, Koen, Smeets, Ann, Deprez, Sabine, and Sunaert, Stefan.
- PDF
12. Assessment of compliance with hormonal therapy in early breast cancer patients with positive hormone receptor phenotype: A single institution study
- Pages 69-74.
- Elsamany, Shereef Ahmed, Alghanmi, Hossam, Albaradei, Abdelrahman, Abdelhamid, Rasha, Madi, Eman, and Ramzan, Amira.
- PDF
13. Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial
- Pages 75-83.
- Cottu, Paul, Ring, Alistair, Abdel-Razeq, Hikmat, Marchetti, Paolo, Cardoso, Fatima, Salvador Bofill, Javier, Martín, Miguel, Menon-Singh, Lakshmi, Wu, Jiwen, and De Laurentiis, Michelino.
- PDF
14. Moderately hypofractionated post-operative radiation therapy for breast cancer: Systematic review and meta-analysis of randomized clinical trials
- Pages 84-92.
- Marta, Gustavo Nader, Riera, Rachel, Pacheco, Rafael Leite, Cabrera Martimbianco, Ana Luiza, Meattini, Icro, Kaidar-Person, Orit, and Poortmans, Philip.
- PDF
15. HER2 copy number quantification in primary tumor and cell-free DNA provides additional prognostic information in HER2 positive early breast cancer
- Pages 114-122.
- Chen, Xiaobin, Lin, Yuxiang, Jiang, Zhengwen, Li, Yan, Zhang, Yihua, Wang, Ying, Yu, Feng, Guo, Wenhui, Chen, Lili, Chen, Minyan, Zhang, Wenzhe, Wang, Chuan, and Fu, Fangmeng.
- PDF
16. Real-world effectiveness of palbociclib plus fulvestrant in advanced breast cancer: Results from a population-based cohort study
- Pages 135-143.
- Cardoso Borges, Fábio, Alves da Costa, Filipa, Ramos, Adriana, Ramos, Catarina, Bernardo, Catarina, Brito, Cláudia, Mayer-da-Silva, Alexandra, Furtado, Cláudia, Ferreira, Arlindo R., Martins-Branco, Diogo, Miranda, Ana, and Lourenço, António.
- PDF
17. Is breast conservation superior to mastectomy in early stage triple negative breast cancer?
- Pages 144-151.
- Saifi, Omran, Chahrour, Mohamad A., Li, Zhuo, Hoballah, Jawad, Panoff, Joseph, Vallow, Laura A., and Zeidan, Youssef H..
- PDF
18. Essential amino acids deprivation is a potential strategy for breast cancer treatment
- Pages 152-161.
- Zhao, Yajie, Pu, Chunrui, and Liu, Zhenzhen.
- PDF
19. Interstitial lung disease in patients treated with Cyclin-Dependent Kinase 4/6 inhibitors: A systematic review and meta-analysis of randomized controlled trials
- Pages 162-169.
- Zhang, Yi, Ma, Zhuo, Sun, Ximu, Feng, Xin, and An, Zhuoling.
- PDF
20. Obstetric complications at time of delivery amongst breast cancer survivors: A population-based cohort study
- Pages 170-178.
- Kaidar-Person, Orit, Yoeli-Ullman, Rakefet, Pillar, Nir, Paluch-Shimon, Shani, Poortmans, Philip, and Lawrence, Yaacov R..
- PDF
21. Effect of dose reductions on clinical outcomes, or of outcomes on dose reductions?
- Pages 179-179.
- Regan, Meredith M..
- PDF
22. Response to: Effect of dose reductions on clinical outcomes, or of outcomes on dose reductions?
- Pages 180-180.
- Ismail, R.K., van Breeschoten, J., Wouters, M.W.J.M., van Dartel, M., van der Flier, S., Reyners, A.K.L., de Graeff, P., Pasmooij, A.M.G., de Boer, A., Broekman, K.E., and Hilarius, D.L..
- PDF
23. RE: The cost impact of unselective vs selective Mamma testing in early-stage breast cancer in Southern Africa
- Pages 181-181.
- Mansani, Fabio Postiglione, and de Freitas-Junior, Ruffo.
- PDF